prednisone + teprotumumab

This is a combination of two drugs, prednisone and teprotumumab, used in the management of thyroid eye disease (TED). Prednisone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties. It acts by modulating gene expression to suppress immune responses and inflammation. Teprotumumab is a fully human monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R), inhibiting its activity. This blockade reduces orbital fibroblast activation, inflammation, and tissue remodeling associated with TED. The combination may be used sequentially or concomitantly in clinical practice for patients with active moderate-to-severe TED to maximize therapeutic benefit[1][3]. Teprotumumab was developed as the first targeted therapy approved for TED.